Estrella Immunopharma, Inc.
ESLA
$0.9286
$0.04064.57%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 550.70K | 424.40K | 444.50K | 945.20K | 1.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.38M | 3.95M | 469.50K | 1.02M | 1.87M |
| Operating Income | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| Income Before Tax | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| Income Tax Expenses | -- | 1.60K | -- | -- | -- |
| Earnings from Continuing Operations | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| EBIT | -3.38M | -3.95M | -469.50K | -1.02M | -1.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.09 | -0.11 | -0.01 | -0.03 | -1.78 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.01 | -0.02 | -1.11 |
| EPS Diluted | -0.09 | -0.11 | -0.01 | -0.03 | -1.78 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.01 | -0.02 | -1.11 |
| Average Basic Shares Outstanding | 36.21M | 36.53M | 35.52M | 35.20M | 1.05M |
| Average Diluted Shares Outstanding | 36.21M | 36.53M | 35.52M | 35.20M | 1.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
